TrippBio, Inc.
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Closed
March 9, 2021Discover our exclusive features for registered users
Understand when and how people have invested in a campaign with our hourly commitments and investor data.
Benefit from AI-powered company descriptions and other important information.
Access financial statements from various sources in one convenient location.
No subscription required - Wixdom is and will remain free to use! Register now to access our industry-leading crowdfunding data.
Sign up for free